Quick Answer
PAVmed Inc. reported Cash and Equivalents of $1.54 million for fiscal year 2025.
PAVmed Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $1.54M | +29.8% |
| 2024 | $1.19M | -94.0% |
| 2023 | $19.64M | -50.6% |
| 2022 | $39.74M | -48.6% |
| 2021 | $77.26M | +347.7% |
| 2020 | $17.26M | +177.5% |
| 2019 | $6.22M | -24.4% |
| 2018 | $8.22M | +435.6% |
| 2017 | $1.54M | +162.1% |
| 2016 | $585.7K | -23.7% |
| 2015 | $767.3K | -8.6% |
| 2014 | $839.1K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2024 | $765.0K | -97.1% | -97.0% |
| June 30, 2024 | $25.50M | -31.4% | -0.1% |
| March 31, 2024 | $25.54M | -48.2% | +30.0% |
| December 31, 2023 | $19.64M | -50.6% | -25.6% |
| September 30, 2023 | $26.41M | -53.5% | -28.9% |
| June 30, 2023 | $37.16M | -43.0% | -24.6% |
| March 31, 2023 | $49.28M | -23.9% | +24.0% |
| December 31, 2022 | $39.74M | -48.6% | -30.0% |
- PAVmed Inc. showed an increase of +29.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2014–2025 period, PAVmed Inc.’s cash and equivalents has grown by 83.3% (from $839.1 thousand to $1.54 million).
- The most recent figure is from PAVmed Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: